NCT06830031 - Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 19, 2025

Primary Completion Date

March 9, 2026

Study Completion Date

May 11, 2026

Conditions

Diffuse Large B-cell-lymphomaDLBCL, Nos Genetic SubtypesFollicular Lymphoma Grade 3BPMBLHGBL With MYC and BCL2 and/or BCL6 RearrangementsHGBL, Nos

Interventions

BIOLOGICAL

C402-CD19-CAR

Enrolled subjects will undergo apheresis to acquire peripheral blood mononuclear cells. C402-CD19-CAR will be generated from the subject's autologous T cells modified from the apheresis product. After C402-CD19-CAR production and product release, subjects will be administered with a single dose of C402-CD19-CAR via subcutaneous injection.

Trial Locations (1)

300020

RECRUITING

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors

collaborator

Institute of Hematology & Blood Diseases Hospital, China

OTHER

lead

Shanghai Exuma Biotechnology Ltd.

INDUSTRY